ALIMENTARY PHARMACOLOGY & THERAPEUTICS消化药理学与治疗学
ALIMENTARY PHARMACOLOGY & THERAPEUTICS(英文缩写 ALIMENT PHARM THER),ISSN 0269-2813,eISSN 1365-2036,中文译名:消化药理学与治疗学 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。
发文量统计区间：2025-11-01 至 2026-10-31，按本站收录文献的发表日期统计。
期刊介绍
历年影响因子趋势
| JCR 数据年份 | 影响因子 | JCR 分区 |
|---|---|---|
| 2021 | 9.524 | Q1 |
| 2022 | 7.600 | Q1 |
| 2023 | 6.600 | Q1 |
| 2024 | 6.700 | Q1 |
| 2025 | 6.800 | Q1 |
ALIMENTARY PHARMACOLOGY & THERAPEUTICS 最新收录文献
-
1. The TOP-GERD Trial: Comparative Efficacy of Tegoprazan Versus Pantoprazole in the Treatment of Erosive Oesophagitis in a Non-Asian Population.
1. TOP-GERD试验：替戈拉生与泮托拉唑在非亚洲人群中治疗糜烂性食管炎的疗效比较PMID:日期:2026-10-03Potassium-competitive acid blockers provide rapid and sustained acid suppression, but tegoprazan has not been studied in non-Asian populations. To compare the efficacy and safety of tegoprazan 50 mg once daily with pantoprazole 40 mg once daily for healing erosive oesophagitis and improving reflux symptoms. In this multicentre, randomized, double-blind, active-controlled trial, Mexican adults with Los Angeles grade B-D erosive oesophagitis received tegoprazan or pantoprazole for 4 weeks. The primary outcome was superior endoscopic healing at week 4. Secondary outcomes included early symptom response, complete symptom resolution, changes in symptom severity, health-related quality of life, and adverse events. Seventy participants were randomized and 64 completed treatments. In the intention-to-treat population, endoscopic healing occurred in 88.9% receiving tegoprazan and 79.4% receiving pantoprazole (p = 0.33). In the per-protocol population, healing occurred in 100% and 84.4%, respectively (p = 0.053). Among participants with Los Angeles grade C or D oesophagitis, per-protocol healing rates were 100% with tegoprazan and 68.8% with pantoprazole (p = 0.04). During the first treatment week, at least 50% symptom improvement occurred in 84.4% and 31.3%, respectively (p < 0.001), and complete symptom resolution was more frequent with tegoprazan from day 1. Symptom severity and health-related quality of life improved in both groups. Adverse events were infrequent, mild, and unrelated to treatment. There was a nonsignificant 9.5% difference in the primary intention-to-treat 4-week healing endpoint between tegoprazan and pantoprazole. Tegoprazan provided faster symptom improvement, while the per-protocol findings and the higher healing rate observed in the exploratory severe oesophagitis subgroup were encouraging and warrant further investigation. (ClinicalTrials.gov Identifier: NCT06991348).
-
2. Letter: The Q425R Variant in Chronic Hepatitis Delta-Distinguishing Cirrhosis Prevalence From Portal Hypertension Severity.
2. 信件：慢性丁型肝炎中的Q425R变异——区分肝硬化患病率与门静脉高压严重程度PMID:日期:2026-10-03该文献暂无摘要。
-
4. Letter: P-CAB Versus PPI for Antithrombotic Gastroprotection: The Importance of Longitudinal Treatment Dynamics-Authors' Reply.
4. 致编辑信：P-CAB与PPI在抗血栓药物胃保护中的比较：纵向治疗动态的重要性——作者回复PMID:日期:2026-10-02该文献暂无摘要。
-
5. Systematic Review: Inclusion of Patients With Difficult-to-Treat Inflammatory Bowel Disease in Randomized Controlled Trials of Advanced Therapies.
5. 系统评价：难治性炎症性肠病患者纳入晚期治疗随机对照试验的情况PMID:日期:2026-10-01Criteria to define difficult-to-treat (DTT) inflammatory bowel disease (IBD) have recently been proposed, yet the inclusion and participation of patients with DTT-IBD in randomized controlled trials (RCTs) are heterogeneous and poorly defined. To explore inclusion and representation of patients with DTT-IBD in RCTs. We reviewed RCTs of advanced therapies (ATs) in ulcerative colitis (UC) and Crohn's disease (CD). DTT-IBD was defined as active disease despite exposure to ATs with ≥ 2 different mechanisms of action. Secondary analyses assessed eligibility and participation of patients exposed to ≥ 1 or ≥ 2 ATs irrespective of mechanism of action, and in CD only, active disease after ≥ 2 intestinal resections and fistulizing disease. We included 179 RCTs, 93 in UC and 86 in CD, comprising 54,258 patients. In UC, 72% (67/93) of studies included patients with prior exposure to ATs and 16.1% (15/93) included participants exposed to agents with ≥ 2 mechanisms of action (DTT); among the 10 trials reporting patient-level data, DTT-UC accounted for 16.2% (814/5019). In CD, 73.3% (63/86) of RCTs included patients with prior exposure to ATs, and 10.5% (9/86) reported patients with DTT-CD due to exposure to multiple classes of ATs. Patients with multifailure DTT-CD accounted for 22.4% (773/3455) of the reported study populations. Subgroup-specific efficacy outcomes for DTT-IBD were not reported, except for one small trial that enrolled only DTT-UC. Few RCTs of advanced medications include patients with DTT-IBD. In most trials, participants with DTT-IBD represent a minority of the study population, and subgroup-specific data are lacking.
-
6. Editorial: Beyond the Matrix-Upadacitinib in Real-World Refractory Crohn's Disease.
PMID:日期:2026-09-26该文献暂无摘要。
-
7. Letter: Proton Pump Inhibitor Prescribing in Autoimmune Gastritis-From Real-World Exposure to Indication-Driven Reassessment.
7. 致编辑的信：自身免疫性胃炎中的质子泵抑制剂处方——从真实世界暴露到适应症驱动的重新评估PMID:日期:2026-09-25该文献暂无摘要。
-
8. Letter: What Does MAPI-Informed ALD Classification Capture?
8. 信件：MAPI 指导下的 ALD 分类捕捉了什么？PMID:日期:2026-09-25该文献暂无摘要。
-
9. Meta-Analysis: The Placebo Response in Modern Treatments for Cholestatic Pruritus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
PMID:日期:2026-09-24Cholestatic pruritus is a debilitating symptom with substantial placebo responses. We aimed to quantify this response and identify trial-level moderators in randomized controlled trials of contemporary therapies. We performed a systematic review and meta-analysis of placebo-controlled trials evaluating ileal bile acid transporter inhibitors or PPAR agonists (searched through March 2026, with a supplementary search on 11 July 2026). Primary outcomes included the standardized mean change (SMC) of pruritus intensity, placebo response rate and mean difference (MD) in Numerical Rating Scale (NRS) and Worst-Itch NRS (WI-NRS) scores. Secondary outcomes included PBC-40 and 5-D Itch scores. We used random-effects models with Hartung-Knapp adjustment and meta-regression. Thirteen trials (n = 548) were analysed. Across placebo groups, pruritus intensity decreased significantly from baseline during follow-up periods of up to 52 weeks. The pooled SMC was -0.49 (95% CI, -0.72 to -0.27) overall, and -0.57 (95% CI, -0.81 to -0.33) for moderate-to-severe pruritus. Pooled response rates were 30.0% (overall) and 27.4% (moderate-to-severe). In moderate-to-severe patients, NRS showed a significant mean reduction of -1.62, whereas the WI-NRS change (-0.65) was not statistically significant. Significant reductions occurred in the PBC-40 itch domain (-2.02) and overall score (-9.13), while 5-D Itch changes were non-significant. None of the evaluated moderators were statistically significant. The magnitude of placebo-associated improvement differed across outcome instruments and may affect estimates and interpretation of treatment effects in cholestatic-pruritus trials. These findings may inform endpoint selection and assumptions used in future trial design. PROSPERO registration number: CRD420261385974.
-
10. Editorial: MetALD-ALD Prediction Index-A Scalable Biomarker for Alcohol Phenotyping Beyond PEth. Authors' Reply.
10. 社论：MetALD-ALD预测指数——一种超越PEth的可扩展酒精表型生物标志物。作者回复PMID:日期:2026-09-24该文献暂无摘要。